Cohort profile: Antiretroviral therapy cohort collaboration (ART-CC)

International Journal of Epidemiology

Volumn 43, Issue 3, 2014, Pages 691-702

  May, Margaret T ^a   Ingle, Suzanne M ^a   Costagliola, Dominique ^b,u,v   Justice, Amy C ^c,d   de Wolf, Frank ^e   Cavassini, Matthias ^f   Monforte, Antonella D'Arminio ^g   Casabona, Jordi ^h   Hogg, Robert S ^i,j   Mocroft, Amanda ^k   Lampe, Fiona C ^k   Dabis, François ^l   Fätkenheuer, Gerd ^m   Sterling, Timothy R ⁿ   del Amo, Julia ^o   Gill, M John ^p   Crane, Heidi M ^q   Saag, Michael S ^r   Guest, Jodie ^s   Brodt, Hans Reinhard ^t   Sterne, Jonathan A C ^a   more..

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SORBONNE UNIVERSITÉ   (France)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g UNIVERSITY OF MILAN   (Italy)

^h Centre d'Estudis Epidemilogics sobre la Sida de Catalunya   (Spain)

ⁱ BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^j SIMON FRASER UNIVERSITY   (Canada)

^k ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^l UNIVERSITÉ DE BORDEAUX   (France)

^m UNIVERSITY OF COLOGNE   (Germany)

ⁿ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o CARLOS III INSTITUTE OF HEALTH   (Spain)

^p UNIVERSITY OF CALGARY   (Canada)

^q UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^r University of Alabama at Birmingham   (United States)

^s ATLANTA VA MEDICAL CENTER   (United States)

^t GOETHE UNIVERSITY   (Germany)

^u INSERM   (France)

^v PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

AIDS; Antiretroviral therapy; Cohort study; HIV; Prognosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; HEMOGLOBIN; LIVER ENZYME; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOMARKER; COHORT ANALYSIS; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; PUBLIC HEALTH; SPATIOTEMPORAL ANALYSIS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CAUSE SPECIFIC SURVIVAL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DATA BASE; EUROPE; FOLLOW UP; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; INFECTION RISK; LIFE EXPECTANCY; MEDICATION COMPLIANCE; MIXED INFECTION; NORTH AMERICA; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; TREATMENT DURATION; VIRUS LOAD; ACQUIRED IMMUNODEFICIENCY SYNDROME; AGE; COINFECTION; DEMOGRAPHY; DRUG EFFECTS; FEMALE; HIV INFECTIONS; PREGNANCY; RISK FACTOR; SEX DIFFERENCE; SOCIOECONOMICS; TIME; TRANSMISSION;

EUROPE; NORTH AMERICA;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AGE FACTORS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COINFECTION; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; NORTH AMERICA; PREGNANCY; PROGNOSIS; RESIDENCE CHARACTERISTICS; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; TIME FACTORS; VIRAL LOAD;

EID: 84902652196     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyt010     Document Type: Article

References (34)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725-30.
2. Gill MJ, May M, Lewden C, Saag M, Mugavero MJ, Reiss P et al. and the Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohorts. Clin Infect Dis 2010;50: 1387-96.
3. May M, Hogg RS, Justice AC, Shepherd B, Costagliola D, Ledergerber B et al. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol 2012;41:1807-20.
4. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360: 119-29.
5. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4(Suppl 1):1-41.
6. British HIV Association (BHIVA) guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012;13(Suppl 2):1-85; available at: http://www.bhiva.org/documents/Guidelines/Treatment/ 2012/hiv1029_2.pdf (24 September 2012, date last accessed).
7. Panel on Antiretroviral Guidelines for adults and adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents.Washington, DC: Department of Health and Human Services; pp. 1-167. Available at: http://aidsinfo.nih.gov/contentfiles/Adultand AdolescentGL002534.pdf (24 September 2012, date last accessed).
8. May M, Royston P, Egger M, Justice AC, Sterne JA. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med 2004;23:2375-98.
9. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:817-24.
10. May M, Boulle A, Phiri S, Messou E, Myer L, Wood R et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376: 449-57.
11. May M, Porter K, Sterne JA, Royston P, Egger M. Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol 2005;58: 1033-41.
12. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003;362: 679-86.
13. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007;21:1185-97.
14. Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chene G et al. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009;23:2199-208.
15. D'Arminio MA, Sabin CA, Phillips A, Sterne J, May M, Justice A et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005;165:416-23.
16. Sabin CA, Phillips AN, Hogg RS, Dabis F, Gill MJ, Reiss P et al. on behalf of the Antiretroviral Therapy (ART) Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS 2005;19: 1995-2000.
17. Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009;48:1138-51.
18. Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008;13:959-67.
19. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006;368:451-58.
20. Zwahlen M, Harris RJ, Hogg R, Costagliola D, May M, de WF et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in eight industrialized countries. Int J Epidemiol 2009;38:1624-33.
21. Hogg R, Lima V, Sterne JAC, Grabar S, Battegay M, Bonarek M et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies 1. Lancet 2008;372:293-99.
22. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352-1363.
23. Babiker AG, Emery S, Fatkenheuer G, Gordin FM, Grund B, Lundgren JD et al. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2012; doi:10.1177/1740774512440342.
24. Murray M, Hogg RS, Lima VD, May MT, Moore DM, Abgrall S et al. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med 2012;13:89-97.
25. Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M et al. Does short-term virologic failure translate to clinical events in antiretroviral-naive patients initiating antiretroviral therapy in clinical practice? AIDS 2008;22: 2481-92.
26. Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R et al. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142, clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr 2011;58:253-60.
27. Girardi E, Sabin CA, D'Arminio MA, Hogg B, Phillips AN, Gill MJ et al. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005;41:1772-82.
28. Brinkhof MW, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007;45:1518-21.
29. Sterne JAC, May M, Sabin C, Phillips A, Costagliola D, Chene G et al. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy-Collaborative analysis of cohorts of HIV-1-Infected patients. J Acquir Immune Defic Syndr 2007; 46:607-15.
30. Moore DM, Harris R, Lima V, Hogg B, May M, Yip B et al. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr 2009;52:357-63.
31. Jarrin I. Sex differences in mortality rates among HIV-positive patients: The Antiretroviral Therapy Cohort Collaboration. Presented at the International AIDS Society Conference (IAS) in July 2011; Rome, Italy.
32. Jarrin I, Del Amo J, the Antiretroviral Therapy Cohort Collaboration (ART-CC). Differences in mortality rates among treated patients according to geographical origin and ethnicity/race; 18th Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, MA, USA.
33. Shepherd BE, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masbeu A et al. Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. AIDS 2012; submitted
34. Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hernan MA. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat 2010; doi:10.2202/1557-4679.1212.